Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
9.78
+0.91 (10.20%)
Jun 3, 2026, 2:17 PM EDT - Market open
Replimune Group Employees
Replimune Group had 479 employees as of March 31, 2025. The number of employees increased by 148 or 44.71% compared to the previous year.
Employees
479
Change (1Y)
148
Growth (1Y)
44.71%
Revenue / Employee
n/a
Profits / Employee
-$657,313
Market Cap
807.15M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 479 | 148 | 44.71% |
| Mar 31, 2024 | 331 | 47 | 16.55% |
| Mar 31, 2023 | 284 | 78 | 37.86% |
| Mar 31, 2022 | 206 | 54 | 35.53% |
| Mar 31, 2021 | 152 | 30 | 24.59% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Phathom Pharmaceuticals | 371 |
| Geron | 258 |
| Omeros | 175 |
| Allogene Therapeutics | 152 |
| Aura Biosciences | 113 |
| Theravance Biopharma | 90 |
| Vor Biopharma | 76 |
| CytomX Therapeutics | 69 |
REPL News
- 2 days ago - Replimune Group trading resumes - TheFly
- 2 days ago - Replimune Group trading halted, volatility trading pause - TheFly
- 2 days ago - Replimune price target raised to $6 from $2 at Wedbush - TheFly
- 2 days ago - Replimune presents final first-in-human data for RP2 alone, with nivolumab - TheFly
- 2 days ago - Replimune presents 3-year overall survival data from IGNYTE trial - TheFly
- 3 days ago - Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - GlobeNewsWire
- 4 days ago - Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - GlobeNewsWire
- 4 days ago - How Replimune's drug got a third chance after the White House intervened - WSJ